Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $1,245 | 10-14 weeks |
Description | Spliceostatin A is an anticancer agent and splicing inhibitor that inhibits the splicing mechanism of the spliceosome and inhibits mitotic clonal expansion and adipogenesis.Spliceostatin A induces cell cycle arrest in the G1 and G2/M phases, and induces apoptosis. |
Targets&IC50 | SF3B1 (mutant):4.9 nM, SF3B1 (WT):5.5 nM |
In vitro | Spliceostatin A (0, 2.5 nM, 5 nM, 10 nM, and 20 nM; 0, 6 h, 12 h, and 24 h) increases apoptosis in chronic lymphocytic leukemia (CLL) cells[1]. |
In vivo | BTA-EG4 (30 mg/kg; injections; daily; 2 weeks) improved dendritic spine density and cognitive function of 3xTg AD mice in an age-dependent manner. BTA-EG4 injected 3xTg AD mice at 6-10 months of age showed improved learning and memory; however, only minimal improvement was observed at 13-16 months of age. This behavioral improvement corresponds to a decrease in soluble Aβ 40 levels. These findings suggest that BTA-EG4 may be beneficial in ameliorating the synaptic loss seen in early AD.[2] |
Molecular Weight | 521.643 |
Formula | C28H43NO8 |
Cas No. | 391611-36-2 |
Storage | keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.